Montelukast in guidelines and beyond

Adv Ther. 2009 Jun;26(6):575-87. doi: 10.1007/s12325-009-0038-1. Epub 2009 Jun 26.

Abstract

In all asthma guidelines, preventive anti-inflammatory treatment is essential in all patients with persistent asthma. Inhaled corticosteroids are the mainstay of treatment in the control of asthma, but other treatments may be used as a monotherapy in patients with mild asthma or as an add-on treatment in those with moderate-to-severe asthma. Leukotriene modifiers are the only validated preventive treatment for all age groups. This review discusses the place of montelukast, a leukotriene receptor antagonist, using guidelines and consensus reports on asthma and rhinitis: the US National Asthma Education and Prevention Program (NAEPP); the British Guideline on the Management of Asthma; the Global Initiative on Asthma (GINA); and Allergic Rhinitis and its Impact on Asthma (ARIA). This review includes new studies that have not yet been considered in guidelines.

Publication types

  • Review

MeSH terms

  • Acetates / therapeutic use*
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Humans
  • Leukotriene Antagonists / therapeutic use*
  • Practice Guidelines as Topic
  • Quinolines / therapeutic use*
  • Rhinitis, Allergic, Seasonal / drug therapy

Substances

  • Acetates
  • Anti-Asthmatic Agents
  • Leukotriene Antagonists
  • Quinolines
  • montelukast